Understanding the Role of Sex Hormones in Cardiovascular Kidney Metabolic Syndrome: Toward Personalized Therapeutic Approaches.

Mustafa Guldan, Selen Unlu, Sama Mahmoud Abdel-Rahman, La��in Ozbek, Abduzhappar Gaipov, Andreea Covic, Maria Jos�� Soler, Adrian Covic, Mehmet Kanbay
Author Information
  1. Mustafa Guldan: Department of Medicine, Ko�� University School of Medicine, 34450 Istanbul, Turkey. ORCID
  2. Selen Unlu: Department of Medicine, Ko�� University School of Medicine, 34450 Istanbul, Turkey.
  3. Sama Mahmoud Abdel-Rahman: Department of Medicine, Ko�� University School of Medicine, 34450 Istanbul, Turkey. ORCID
  4. La��in Ozbek: Department of Medicine, Ko�� University School of Medicine, 34450 Istanbul, Turkey. ORCID
  5. Abduzhappar Gaipov: Department of Medicine, School of Medicine, Nazarbayev University, Astana 010000, Kazakhstan. ORCID
  6. Andreea Covic: Department of Nephrology, Grigore T. Popa University of Medicine, 700115 Iasi, Romania.
  7. Maria Jos�� Soler: Nephrology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Research, 08035 Barcelona, Spain. ORCID
  8. Adrian Covic: Department of Nephrology, Grigore T. Popa University of Medicine, 700115 Iasi, Romania. ORCID
  9. Mehmet Kanbay: Division of Nephrology, Department of Medicine, Ko�� University School of Medicine, 34450 Istanbul, Turkey. ORCID

Abstract

Cardiovascular kidney metabolic (CKM) syndrome represents a complex interplay of cardiovascular disease (CVD), chronic kidney disease (CKD), and metabolic comorbidities, posing a significant public health challenge. Gender exerts a critical influence on CKM syndrome, affecting the disease severity and onset through intricate interactions involving sex hormones and key physiological pathways such as the renin-angiotensin system, oxidative stress, inflammation, vascular disease and insulin resistance. It is widely known that beyond the contribution of traditional risk factors, men and women exhibit significant differences in CKM syndrome and its components, with distinct patterns observed in premenopausal women and postmenopausal women compared to men. Despite women generally experiencing a lower incidence of CVD, their outcomes following cardiovascular events are often worse compared to men. The disparities also extend to the treatment approaches for kidney failure, with a higher prevalence of dialysis among men despite women exhibiting higher rates of CKD. The impact of endogenous sex hormones, the correlations between CKM and its components, as well as the long-term effects of treatment modalities using sex hormones, including hormone replacement therapies and gender-affirming therapies, have drawn attention to this topic. Current research on CKM syndrome is hindered by the scarcity of large-scale studies and insufficient integration of gender-specific considerations into treatment strategies. The underlying mechanisms driving the gender disparities in the pathogenesis of CKM syndrome, including the roles of estrogen, progesterone and testosterone derivatives, remain poorly understood, thus limiting their application in personalized therapeutic interventions. This review synthesizes existing knowledge to clarify the intricate relationship between sex hormones, gender disparities, and the progression of CVD within CKM syndrome. By addressing these knowledge gaps, this study aims to guide future research efforts and promote tailored approaches for effectively managing CKD syndrome.

Keywords

References

  1. PLoS One. 2023 Sep 28;18(9):e0292159 [PMID: 37768964]
  2. Am J Nephrol. 2008;28(3):397-404 [PMID: 18063858]
  3. Menopause. 2018 Nov;25(11):1262-1274 [PMID: 30358722]
  4. Curr Pharm Des. 2016;22(25):3835-52 [PMID: 26956230]
  5. J Hypertens. 2012 Dec;30(12):2387-94 [PMID: 23111623]
  6. Clin J Am Soc Nephrol. 2022 Sep;17(9):1305-1315 [PMID: 35973728]
  7. Nat Rev Cardiol. 2023 Jul;20(7):463-474 [PMID: 36977782]
  8. Metabolism. 1991 Dec;40(12):1323-6 [PMID: 1961129]
  9. Int J Mol Sci. 2020 Jun 17;21(12): [PMID: 32560398]
  10. Biochem Cell Biol. 2013 Jun;91(3):148-54 [PMID: 23668787]
  11. Climacteric. 2006 Apr;9(2):108-18 [PMID: 16698657]
  12. J Hum Hypertens. 2022 Feb;36(2):120-125 [PMID: 34230581]
  13. Ther Adv Endocrinol Metab. 2010 Oct;1(5):207-23 [PMID: 23148165]
  14. Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11765-70 [PMID: 11562484]
  15. Trends Cardiovasc Med. 2010 Apr;20(3):73-8 [PMID: 21130949]
  16. J Am Soc Nephrol. 2006 Dec;17(12 Suppl 3):S231-5 [PMID: 17130267]
  17. Nephrol Dial Transplant. 2009 Jun;24(6):1753-8 [PMID: 19131350]
  18. J Steroid Biochem Mol Biol. 2015 Mar;147:1-9 [PMID: 25448746]
  19. Aging Male. 2013 Jun;16(2):58-66 [PMID: 23581721]
  20. Am J Physiol Heart Circ Physiol. 2019 Aug 1;317(2):H243-H254 [PMID: 31149843]
  21. Clin Kidney J. 2022 Jan 31;15(6):1144-1151 [PMID: 35664281]
  22. PLoS One. 2022 May 25;17(5):e0268759 [PMID: 35613118]
  23. Kidney Int. 1996 Oct;50(4):1173-9 [PMID: 8887275]
  24. Can J Cardiol. 2016 Aug;32(8):1017-25 [PMID: 26860777]
  25. Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12729-34 [PMID: 11070086]
  26. Methods Mol Biol. 2021;2216:27-44 [PMID: 33475992]
  27. J Cardiovasc Electrophysiol. 2005 Mar;16(3):278-84 [PMID: 15817086]
  28. Circulation. 1997 Sep 16;96(6):1953-63 [PMID: 9323086]
  29. Curr Obes Rep. 2021 Dec;10(4):458-466 [PMID: 34599745]
  30. J Biol Chem. 2006 Jul 21;281(29):20349-56 [PMID: 16682413]
  31. Kidney Int Suppl (2011). 2022 Apr;12(1):7-11 [PMID: 35529086]
  32. J Gerontol A Biol Sci Med Sci. 2012 Dec;67(12):1358-64 [PMID: 22843670]
  33. Hypertension. 2013 Mar;61(3):730-6 [PMID: 23339165]
  34. Wien Klin Wochenschr. 2023 Feb;135(3-4):89-96 [PMID: 36044092]
  35. Int J Impot Res. 2022 Nov;34(7):704-713 [PMID: 35102263]
  36. J Clin Endocrinol Metab. 2008 Jan;93(1):131-8 [PMID: 17925335]
  37. Int J Mol Sci. 2021 Apr 20;22(8): [PMID: 33923905]
  38. Vascul Pharmacol. 2023 Oct;152:107209 [PMID: 37591444]
  39. PLoS One. 2016 Dec 15;11(12):e0168255 [PMID: 27977752]
  40. Am J Physiol Regul Integr Comp Physiol. 2017 Jul 1;313(1):R51-R57 [PMID: 28438762]
  41. Kidney Int. 2013 Jun;83(6):1118-29 [PMID: 23447063]
  42. Cardiovasc Res. 2002 Feb 15;53(3):672-7 [PMID: 11861038]
  43. Exp Gerontol. 2022 Mar;159:111680 [PMID: 34973347]
  44. ILAR J. 2004;45(2):160-9 [PMID: 15111735]
  45. N Engl J Med. 2003 Aug 7;349(6):535-45 [PMID: 12904518]
  46. Surgery. 2014 Aug;156(2):243-52 [PMID: 24957669]
  47. Circ Res. 2006 Sep 1;99(5):459-61 [PMID: 16946140]
  48. JAMA. 2002 Jul 17;288(3):321-33 [PMID: 12117397]
  49. Endocrinology. 2021 Nov 1;162(11): [PMID: 34467976]
  50. J Endocrinol Invest. 2022 Oct;45(10):1875-1885 [PMID: 35689728]
  51. Redox Biol. 2020 Apr;31:101490 [PMID: 32169396]
  52. Clin Auton Res. 2020 Oct;30(5):393-408 [PMID: 32860555]
  53. Clin Exp Hypertens. 1993 Jan;15(1):153-70 [PMID: 8385524]
  54. Am J Cardiol. 2002 Jul 3;90(1A):3F-6F [PMID: 12106632]
  55. JAMA. 2009 May 13;301(18):1892-901 [PMID: 19436016]
  56. Endocrinology. 2019 Apr 1;160(4):772-781 [PMID: 30753403]
  57. Am J Cardiol. 2002 Jun 20;89(12A):12E-17E; discussion 17E-18E [PMID: 12084397]
  58. J Clin Endocrinol Metab. 1999 Oct;84(10):3673-80 [PMID: 10523013]
  59. Cardiorenal Med. 2014 Apr;4(1):1-11 [PMID: 24847329]
  60. Cell Physiol Biochem. 2009;23(1-3):75-86 [PMID: 19255502]
  61. Kidney Int Suppl. 2008 Dec;(111):S4-9 [PMID: 19034325]
  62. J Natl Cancer Inst. 2010 Jan 6;102(1):39-46 [PMID: 19996060]
  63. Can J Cardiol. 2022 Dec;38(12):1854-1864 [PMID: 36156286]
  64. In Vivo. 2014 Nov-Dec;28(6):1097-100 [PMID: 25398805]
  65. Front Immunol. 2018 Jun 12;9:1332 [PMID: 29946321]
  66. Am J Kidney Dis. 2021 Aug;78(2):200-209.e1 [PMID: 33857532]
  67. Endocrinology. 2016 Apr;157(4):1590-600 [PMID: 26872089]
  68. Mol Cell Endocrinol. 2014 Feb 15;382(2):909-14 [PMID: 24275180]
  69. Cancer J. 2022 May-Jun 01;28(3):208-223 [PMID: 35594469]
  70. Endocrinology. 1998 Dec;139(12):4832-8 [PMID: 9832419]
  71. JAMA. 1998 Aug 19;280(7):605-13 [PMID: 9718051]
  72. Nature. 2006 Dec 14;444(7121):881-7 [PMID: 17167477]
  73. Biogerontology. 2024 Jun;25(3):399-414 [PMID: 38349436]
  74. Circulation. 2023 Nov 14;148(20):1636-1664 [PMID: 37807920]
  75. Am J Physiol Renal Physiol. 2005 Nov;289(5):F941-8 [PMID: 16210452]
  76. Diabetes. 1994 Nov;43(11):1271-8 [PMID: 7926300]
  77. Am J Physiol Renal Physiol. 2000 Oct;279(4):F664-70 [PMID: 10997916]
  78. Nephrology (Carlton). 2021 Mar;26(3):217-226 [PMID: 33058388]
  79. Diabetes Obes Metab. 2022 Dec;24(12):2283-2296 [PMID: 35929483]
  80. Am J Physiol Regul Integr Comp Physiol. 2021 Mar 1;320(3):R297-R306 [PMID: 33407017]
  81. J Clin Endocrinol Metab. 2000 May;85(5):1834-40 [PMID: 10843161]
  82. Circulation. 2007 Jun 26;115(25):3197-204 [PMID: 17562954]
  83. FASEB J. 1999 Jul;13(10):1137-43 [PMID: 10385605]
  84. Biochem Biophys Res Commun. 1998 Jul 30;248(3):523-6 [PMID: 9703958]
  85. Kidney Int. 2011 Feb;79(4):404-13 [PMID: 20962747]
  86. JAMA. 2004 Apr 14;291(14):1701-12 [PMID: 15082697]
  87. J Steroid Biochem Mol Biol. 2014 Jul;142:68-75 [PMID: 23851166]
  88. Kidney Int. 2009 Jun;75(11):1194-1201 [PMID: 19279558]
  89. Wien Med Wochenschr. 2011 Mar;161(5-6):109-16 [PMID: 21461800]
  90. J Gen Physiol. 1997 Aug;110(2):135-40 [PMID: 9236206]
  91. Am J Kidney Dis. 2004 Feb;43(2):244-53 [PMID: 14750089]
  92. J Surg Res. 2010 Nov;164(1):e1-11 [PMID: 20850791]
  93. Front Neuroendocrinol. 2008 May;29(2):169-81 [PMID: 18093638]
  94. J Mol Cell Cardiol. 2016 Aug;97:245-62 [PMID: 27262674]
  95. Endocr Pract. 2023 Jun;29(6):498-507 [PMID: 36603652]
  96. Circulation. 2006 Oct 24;114(17):1829-37 [PMID: 17030678]
  97. J Lipid Res. 2016 Aug;57(8):1541-51 [PMID: 27354419]
  98. Circulation. 2002 Sep 3;106(10):1224-8 [PMID: 12208797]
  99. J Am Soc Nephrol. 2019 Jan;30(1):137-146 [PMID: 30510134]
  100. Int J Endocrinol. 2020 Nov 12;2020:8849641 [PMID: 33273918]
  101. Int J Obes Relat Metab Disord. 2002 Feb;26(2):193-9 [PMID: 11850750]
  102. Future Cardiol. 2021 Mar;17(2):347-353 [PMID: 33191784]
  103. Croat Med J. 2016 Apr 23;57(2):100-9 [PMID: 27106352]
  104. Curr Diab Rep. 2018 Jul 30;18(9):69 [PMID: 30058013]
  105. J Endocrinol. 2016 Apr;229(1):R1-R16 [PMID: 26769913]
  106. Hypertension. 1999 Oct;34(4 Pt 2):920-3 [PMID: 10523385]
  107. Biochem Biophys Res Commun. 2001 Sep 7;286(5):1153-7 [PMID: 11527420]
  108. Eur J Endocrinol. 2003 Dec;149(6):601-8 [PMID: 14641004]
  109. Med Sci Monit. 2009 May;15(5):CR211-6 [PMID: 19396035]
  110. Am J Physiol Cell Physiol. 2005 Jan;288(1):C57-64 [PMID: 15385267]
  111. Diabetes Obes Metab. 2006 Sep;8(5):538-54 [PMID: 16918589]
  112. Am J Epidemiol. 2012 Mar 1;175(5):423-31 [PMID: 22306563]
  113. Curr Cardiol Rep. 2022 Dec;24(12):1791-1798 [PMID: 36269533]
  114. Cell Physiol Biochem. 2012;30(1):1-12 [PMID: 22759951]
  115. Atherosclerosis. 2022 Jan;341:71-79 [PMID: 34785061]
  116. Circ Res. 2004 Oct 1;95(7):692-9 [PMID: 15345655]
  117. Am J Cardiol. 1984 Sep 1;54(6):582-6 [PMID: 6475777]
  118. Front Pharmacol. 2022 Apr 12;13:850815 [PMID: 35496275]
  119. Cardiorenal Med. 2018;8(4):296-301 [PMID: 30089281]
  120. Hypertension. 2000 Dec;36(6):970-4 [PMID: 11116109]
  121. J Steroid Biochem Mol Biol. 2010 Oct;122(1-3):65-73 [PMID: 20035866]
  122. Can J Kidney Health Dis. 2021 Jan 20;8:2054358120985379 [PMID: 33552529]
  123. Adv Chronic Kidney Dis. 2016 Jan;23(1):19-28 [PMID: 26709059]
  124. Int J Endocrinol. 2014;2014:527470 [PMID: 24688542]
  125. Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4130-5 [PMID: 15024130]
  126. Hormones (Athens). 2022 Dec;21(4):545-554 [PMID: 35841524]
  127. Curr Oncol. 2021 Aug 28;28(5):3331-3346 [PMID: 34590590]
  128. Cardiovasc Res. 2010 Mar 1;85(4):719-28 [PMID: 19861308]
  129. Clin Exp Pharmacol Physiol. 2021 Jul;48(7):978-986 [PMID: 33711175]
  130. JAMA. 1990 Feb 23;263(8):1092-6 [PMID: 2299781]
  131. Pharmacol Ther. 2016 Aug;164:1-81 [PMID: 27130806]
  132. Kidney Int. 1999 Apr;55(4):1268-76 [PMID: 10200990]
  133. Am J Pathol. 2021 Sep;191(9):1490-1498 [PMID: 34102108]
  134. J Steroid Biochem Mol Biol. 2020 Feb;196:105496 [PMID: 31655180]
  135. J Am Coll Cardiol. 2003 Jan 15;41(2):300-6 [PMID: 12535826]
  136. Int J Cardiol. 2013 Oct 12;168(5):4755-60 [PMID: 23962778]
  137. Nat Rev Endocrinol. 2024 Jan;20(1):50-61 [PMID: 37872302]
  138. J Endocrinol Invest. 2016 Sep;39(9):967-81 [PMID: 27241317]
  139. Biol Sex Differ. 2020 Jun 1;11(1):31 [PMID: 32487164]
  140. Nephrol Dial Transplant. 2010 Feb;25(2):469-77 [PMID: 19762608]
  141. Int J Mol Sci. 2020 May 04;21(9): [PMID: 32375307]
  142. J Cardiovasc Pharmacol Ther. 1997 Jan;2(1):47-52 [PMID: 10684441]
  143. Cells. 2022 Nov 29;11(23): [PMID: 36497080]
  144. Kidney Blood Press Res. 2001;24(3):159-65 [PMID: 11528208]
  145. Adv Exp Med Biol. 2017;960:1-17 [PMID: 28585193]
  146. Endocr Pract. 2007 Oct;13(6):629-35 [PMID: 17954419]
  147. Am J Physiol. 1995 Jun;268(6 Pt 2):H2569-73 [PMID: 7611507]
  148. Oxid Med Cell Longev. 2014;2014:713894 [PMID: 25614777]
  149. Am J Physiol Heart Circ Physiol. 2022 Aug 1;323(2):H336-H349 [PMID: 35749718]
  150. J Clin Endocrinol Metab. 1998 Mar;83(3):847-50 [PMID: 9506738]
  151. Lancet. 1995 Jul 8;346(8967):89-90 [PMID: 7603219]
  152. J Hypertens. 1989 Sep;7(9):721-6 [PMID: 2529310]
  153. Cardiovasc Res. 1996 Nov;32(5):980-5 [PMID: 8944830]
  154. Am J Kidney Dis. 2006 Nov;48(5):752-60 [PMID: 17059994]
  155. Mol Biol Cell. 2013 Dec;24(24):3805-18 [PMID: 24152730]
  156. Mol Endocrinol. 2002 Oct;16(10):2181-7 [PMID: 12351684]
  157. J Cell Physiol. 1999 Jan;178(1):35-43 [PMID: 9886488]
  158. Cardiovasc Res. 2002 Feb 15;53(3):605-19 [PMID: 11861031]
  159. Biochem Biophys Res Commun. 2009 Sep 25;387(3):531-6 [PMID: 19615976]
  160. Circulation. 1997 Jan 7;95(1):39-45 [PMID: 8994414]
  161. Life Sci. 2016 Aug 15;159:20-29 [PMID: 26939577]
  162. J Steroid Biochem Mol Biol. 2008 Apr;109(3-5):254-7 [PMID: 18472261]
  163. J Am Soc Nephrol. 2004 Feb;15(2):348-58 [PMID: 14747381]
  164. PLoS One. 2011;6(11):e27457 [PMID: 22096576]
  165. Curr Heart Fail Rep. 2022 Aug;19(4):200-212 [PMID: 35624387]
  166. Mol Med Rep. 2014 Jun;9(6):2061-8 [PMID: 24682292]
  167. Am J Cardiol. 1999 Feb 1;83(3):354-9 [PMID: 10072223]
  168. Pediatr Nephrol. 2022 Sep;37(9):2141-2150 [PMID: 35083530]
  169. Circ Res. 2011 Sep 2;109(6):687-96 [PMID: 21885836]
  170. Int J Obes (Lond). 2015 Oct;39(10):1539-47 [PMID: 26032810]
  171. Kidney Int. 2004 Apr;65(4):1252-61 [PMID: 15086464]
  172. BJOG. 2002 Sep;109(9):1056-62 [PMID: 12269682]
  173. Am J Physiol Renal Physiol. 2013 Apr 1;304(7):F875-82 [PMID: 23364800]
  174. Front Pharmacol. 2017 Sep 11;8:604 [PMID: 28955223]
  175. Endocrinology. 2008 May;149(5):2361-8 [PMID: 18276764]
  176. J Hum Hypertens. 2023 Aug;37(8):609-618 [PMID: 36319856]
  177. Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12735-40 [PMID: 11070087]
  178. Curr Opin Nephrol Hypertens. 2019 Jan;28(1):1-9 [PMID: 30320621]
  179. Ann N Y Acad Sci. 2020 Feb;1461(1):127-143 [PMID: 31868931]
  180. Life Sci. 2020 Sep 15;257:118138 [PMID: 32712298]
  181. J Am Coll Cardiol. 2020 Feb 4;75(4):422-434 [PMID: 32000955]
  182. Arch Intern Med. 2004 Sep 13;164(16):1737-48 [PMID: 15364666]
  183. Gastroenterology. 2007 May;132(6):2169-80 [PMID: 17498510]
  184. Metabolism. 2011 Mar;60(3):438-43 [PMID: 20494377]
  185. PLoS One. 2021 Jan 22;16(1):e0245166 [PMID: 33481861]
  186. Atherosclerosis. 2012 Nov;225(1):180-6 [PMID: 22981430]
  187. Menopause. 2019 Nov;26(11):1327-1333 [PMID: 31567869]
  188. J Endocrinol. 2009 Aug;202(2):299-307 [PMID: 19474060]
  189. Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9614-9 [PMID: 12878732]
  190. Metabolism. 2013 Apr;62(4):457-78 [PMID: 22999785]
  191. BJU Int. 2007 Nov;100(5):1060-5 [PMID: 17868420]
  192. Mayo Clin Proc. 2019 Jul;94(7):1339-1356 [PMID: 31272577]
  193. J Cardiovasc Pharmacol. 2018 Mar;71(3):147-154 [PMID: 29112589]
  194. Horm Metab Res. 2004 Apr;36(4):197-202 [PMID: 15114516]
  195. Exp Ther Med. 2019 Mar;17(3):2373-2380 [PMID: 30783489]
  196. Cochrane Database Syst Rev. 2012 Oct 17;10:CD000188 [PMID: 23076884]
  197. Int J Obes (Lond). 2020 Jun;44(6):1264-1278 [PMID: 32060355]
  198. J Clin Invest. 1989 Jun;83(6):1941-5 [PMID: 2723066]
  199. J Biol Chem. 2010 Mar 5;285(10):7537-44 [PMID: 20048160]
  200. Int J Obes Relat Metab Disord. 2000 Jun;24 Suppl 2:S59-63 [PMID: 10997611]
  201. Curr Probl Cardiol. 2024 Feb;49(2):102344 [PMID: 38103820]
  202. Maturitas. 2017 May;99:27-36 [PMID: 28364865]
  203. Compr Physiol. 2018 Sep 14;8(4):1253-1290 [PMID: 30215860]
  204. Rev Endocr Metab Disord. 2015 Sep;16(3):249-68 [PMID: 26590935]
  205. J Biol Chem. 2005 Jul 15;280(28):26339-48 [PMID: 15899894]
  206. Diabetes Res Clin Pract. 2022 Jun;188:109924 [PMID: 35584716]
  207. Gen Comp Endocrinol. 2010 Apr 1;166(2):356-64 [PMID: 20005231]
  208. J Clin Invest. 2003 Dec;112(12):1796-808 [PMID: 14679176]
  209. Am J Physiol Regul Integr Comp Physiol. 2010 Nov;299(5):R1387-95 [PMID: 20702799]
  210. Menopause. 2011 Aug;18(8):906-14 [PMID: 21471825]
  211. Physiol Rev. 2013 Jan;93(1):137-88 [PMID: 23303908]

Word Cloud

Created with Highcharts 10.0.0syndromeCKMkidneydiseasesexwomenmetabolichormonesmencardiovascularCVDCKDdisparitiestreatmentCardiovascularchronicsignificantintricatecomponentscomparedapproacheshigherincludinghormonetherapiesresearchgenderknowledgerepresentscomplexinterplaycomorbiditiesposingpublichealthchallengeGenderexertscriticalinfluenceaffectingseverityonsetinteractionsinvolvingkeyphysiologicalpathwaysrenin-angiotensinsystemoxidativestressinflammationvascularinsulinresistancewidelyknownbeyondcontributiontraditionalriskfactorsexhibitdifferencesdistinctpatternsobservedpremenopausalpostmenopausalDespitegenerallyexperiencinglowerincidenceoutcomesfollowingeventsoftenworsealsoextendfailureprevalencedialysisamongdespiteexhibitingratesimpactendogenouscorrelationswelllong-termeffectsmodalitiesusingreplacementgender-affirmingdrawnattentiontopicCurrenthinderedscarcitylarge-scalestudiesinsufficientintegrationgender-specificconsiderationsstrategiesunderlyingmechanismsdrivingpathogenesisrolesestrogenprogesteronetestosteronederivativesremainpoorlyunderstoodthuslimitingapplicationpersonalizedtherapeuticinterventionsreviewsynthesizesexistingclarifyrelationshipprogressionwithinaddressinggapsstudyaimsguidefutureeffortspromotetailoredeffectivelymanagingUnderstandingRoleSexHormonesKidneyMetabolicSyndrome:TowardPersonalizedTherapeuticApproachesdiabetesmellitus

Similar Articles

Cited By